Minodronic acid

Drug Profile

Minodronic acid

Alternative Names: Bonoteo Tablets; Minodron; Minodronate; ONO-5920; Onobis®; Recalbon Tablets; YH 529; YM 529

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; Ono Pharmaceutical
  • Class Antineoplastics; Bisphosphonates; Calcium regulators; Imidazoles; Osteoporosis therapies; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Osteoporosis
  • Discontinued Cancer metastases; Hypercalcaemia; Multiple myeloma

Most Recent Events

  • 31 Aug 2017 Ono Pharmaceutical suspends patient enrolment in a phase II trial for Osteoporosis in Japan (PO) (UMIN000021242)
  • 16 Sep 2016 Pharmacokinetics data from preclinical studies in Osteoporosis was presented at the 38th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2016)
  • 16 Sep 2011 Launched for Osteoporosis (intermittent therapy) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top